Does the media refer more to BMY or AMGN?

In the previous week, Bristol Myers Squibb had 16 more articles in the media than Amgen. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 52 mentions for Amgen. Bristol Myers Squibb's average media sentiment score of 1.09 beat Amgen's score of 1.07 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 42 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 33 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to BMY or EXEL?

In the previous week, Bristol Myers Squibb had 53 more articles in the media than Exelixis. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 15 mentions for Exelixis. Exelixis' average media sentiment score of 1.38 beat Bristol Myers Squibb's score of 1.09 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 42 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMY or GILD?

In the previous week, Bristol Myers Squibb had 12 more articles in the media than Gilead Sciences. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 56 mentions for Gilead Sciences. Bristol Myers Squibb's average media sentiment score of 1.09 beat Gilead Sciences' score of 0.96 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 42 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 34 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer VRTX or BMY?

In the previous week, Bristol Myers Squibb had 26 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 42 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Bristol Myers Squibb's score of 1.09 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 29 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 42 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to BMY or ABBV?

In the previous week, AbbVie had 7 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 75 mentions for AbbVie and 68 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.09 beat AbbVie's score of 0.95 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 42 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 44 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Bristol Myers Squibb (BMY) Competitors

$64.98 +1.88 (+2.98%)

Closing price 07/30/2026 03:59 PM Eastern

Extended Trading

$64.46 -0.52 (-0.80%)

As of 04:47 AM Eastern

Compare

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you buy Bristol Myers Squibb stock or one of its competitors? MarketBeat compares Bristol Myers Squibb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Bristol Myers Squibb compare to Amgen?

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Bristol Myers Squibb has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.6%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Amgen has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb presently has a consensus price target of $61.25, indicating a potential downside of 5.74%. Amgen has a consensus price target of $357.00, indicating a potential downside of 7.90%. Given Bristol Myers Squibb's higher probable upside, research analysts clearly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Amgen has a net margin of 20.96% compared to Bristol Myers Squibb's net margin of 15.01%. Amgen's return on equity of 137.41% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Amgen	20.96%	137.41%	13.28%

In the previous week, Bristol Myers Squibb had 16 more articles in the media than Amgen. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 52 mentions for Amgen. Bristol Myers Squibb's average media sentiment score of 1.09 beat Amgen's score of 1.07 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	42 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	33 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.75	$7.05B	$3.56	18.25
Amgen	$36.75B	5.69	$7.71B	$14.37	26.98

Summary

Amgen beats Bristol Myers Squibb on 14 of the 20 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Bristol Myers Squibb (NYSE:BMY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.75	$7.05B	$3.56	18.25
Exelixis	$2.38B	5.92	$782.57M	$3.01	18.59

In the previous week, Bristol Myers Squibb had 53 more articles in the media than Exelixis. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 15 mentions for Exelixis. Exelixis' average media sentiment score of 1.38 beat Bristol Myers Squibb's score of 1.09 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	42 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Exelixis	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.08% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Exelixis	35.08%	39.89%	30.23%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bristol Myers Squibb has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Bristol Myers Squibb presently has a consensus target price of $61.25, suggesting a potential downside of 5.74%. Exelixis has a consensus target price of $49.29, suggesting a potential downside of 11.94%. Given Bristol Myers Squibb's higher probable upside, equities research analysts clearly believe Bristol Myers Squibb is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
Exelixis	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Summary

Exelixis beats Bristol Myers Squibb on 9 of the 15 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Bristol Myers Squibb (NYSE:BMY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Bristol Myers Squibb had 12 more articles in the media than Gilead Sciences. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 56 mentions for Gilead Sciences. Bristol Myers Squibb's average media sentiment score of 1.09 beat Gilead Sciences' score of 0.96 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	42 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	34 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of 30.99% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Gilead Sciences	30.99%	48.19%	18.28%

Bristol Myers Squibb has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Bristol Myers Squibb currently has a consensus price target of $61.25, indicating a potential downside of 5.74%. Gilead Sciences has a consensus price target of $157.93, indicating a potential upside of 20.30%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gilead Sciences has lower revenue, but higher earnings than Bristol Myers Squibb. Gilead Sciences is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.75	$7.05B	$3.56	18.25
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.89

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Gilead Sciences beats Bristol Myers Squibb on 12 of the 19 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Vertex Pharmaceuticals currently has a consensus target price of $559.61, indicating a potential upside of 16.17%. Bristol Myers Squibb has a consensus target price of $61.25, indicating a potential downside of 5.74%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35

In the previous week, Bristol Myers Squibb had 26 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 68 mentions for Bristol Myers Squibb and 42 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Bristol Myers Squibb's score of 1.09 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	29 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	42 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Bristol Myers Squibb	15.01%	64.87%	13.16%

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.19	$3.95B	$16.86	28.57
Bristol Myers Squibb	$48.19B	2.75	$7.05B	$3.56	18.25

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 12 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

Bristol Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Bristol Myers Squibb currently has a consensus price target of $61.25, indicating a potential downside of 5.74%. AbbVie has a consensus price target of $269.29, indicating a potential upside of 4.55%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Bristol Myers Squibb has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AbbVie had 7 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 75 mentions for AbbVie and 68 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.09 beat AbbVie's score of 0.95 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	42 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	44 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher earnings, but lower revenue than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.75	$7.05B	$3.56	18.25
AbbVie	$61.16B	7.44	$4.23B	$2.03	126.88

Bristol Myers Squibb has a net margin of 15.01% compared to AbbVie's net margin of 5.79%. Bristol Myers Squibb's return on equity of 64.87% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
AbbVie	5.79%	-576.45%	13.39%

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.9%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has raised its dividend for 17 consecutive years and AbbVie has raised its dividend for 53 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

AbbVie beats Bristol Myers Squibb on 12 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bristol Myers Squibb	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$128.85B	$3.71B	$7.04B	$23.53B
Dividend Yield	3.99%	2.13%	2.65%	4.19%
P/E Ratio	18.25	23.35	27.65	30.73
Price / Sales	2.75	183.26	490.18	81.99
Price / Cash	7.76	165.25	51.74	31.18
Price / Book	7.15	8.05	10.05	4.66
Net Income	$7.05B	$23.81M	$3.60B	$1.07B
7 Day Performance	4.73%	0.21%	0.67%	0.55%
1 Month Performance	12.77%	-6.22%	-3.28%	1.58%
1 Year Performance	49.82%	41.74%	24.49%	17.66%

Bristol Myers Squibb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bristol Myers Squibb	4.1741 of 5 stars	$64.98 +3.0%	$61.25 -5.7%	+41.2%	$128.85B	$48.19B	18.25	32,500	Trending News Earnings Report Options Volume
AMGN Amgen	3.9925 of 5 stars	$371.50 +1.5%	$356.62 -4.0%	+28.6%	$197.56B	$36.75B	25.85	31,500	Trending News Upcoming Earnings Analyst Forecast Gap Down
EXEL Exelixis	2.8358 of 5 stars	$55.65 +1.2%	$49.00 -11.9%	+51.9%	$13.82B	$2.32B	18.49	1,077	Positive News Upcoming Earnings
GILD Gilead Sciences	4.9017 of 5 stars	$130.86 +0.4%	$158.33 +21.0%	+14.4%	$161.83B	$29.44B	17.83	17,000	Trending News Upcoming Earnings Analyst Forecast Analyst Revision Gap Down
VRTX Vertex Pharmaceuticals	4.2309 of 5 stars	$473.09 +0.1%	$559.61 +18.3%	+2.7%	$119.94B	$12.00B	28.06	6,400	Trending News Upcoming Earnings Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Which has more risk and volatility, BMY or AMGN?

Is BMY or AMGN a better dividend stock?

Do analysts prefer BMY or AMGN?

Is BMY or AMGN more profitable?

Does the media refer more to BMY or AMGN?

Do insiders & institutionals believe in BMY or AMGN?

Which has higher earnings and valuation, BMY or AMGN?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Which has preferable earnings and valuation, BMY or EXEL?

Does the media refer more to BMY or EXEL?

Is BMY or EXEL more profitable?

Do insiders & institutionals hold more shares of BMY or EXEL?

Which has more volatility & risk, BMY or EXEL?

Do analysts recommend BMY or EXEL?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Does the media favor BMY or GILD?

Is BMY or GILD more profitable?

Which has more volatility and risk, BMY or GILD?

Do analysts rate BMY or GILD?

Do insiders & institutionals believe in BMY or GILD?

Which has higher valuation & earnings, BMY or GILD?

Is BMY or GILD a better dividend stock?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Do analysts rate VRTX or BMY?

Does the media prefer VRTX or BMY?

Which has more volatility and risk, VRTX or BMY?

Is VRTX or BMY more profitable?

Which has higher valuation & earnings, VRTX or BMY?

Do insiders & institutionals have more ownership in VRTX or BMY?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Do analysts recommend BMY or ABBV?

Which has more risk & volatility, BMY or ABBV?

Do institutionals and insiders hold more shares of BMY or ABBV?

Does the media refer more to BMY or ABBV?

Which has stronger valuation and earnings, BMY or ABBV?

Is BMY or ABBV more profitable?

Is BMY or ABBV a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools